Invesco国际成长焦点主动型ETF MTRA 深 沪
已收盘 10-30 16:00:00 美东时间
25.1963
-0.574
-2.23%
华盛通- 最 高25.1963
- 今 开25.7699
- 成交量 8股
- 最 低 25.1963
- 昨 收 25.7699
- 总市值 1.30亿
- 52周最高 27.70
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 23.3326
- 委 比 0.00%
- 总股本 516.08万
- 历史最高 27.70
- 量 比 0.02
- 振 幅 0.00%
- 历史最低 23.3326
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the 2026 SITC meeting. The combination, the first of two T cell engagers in a solid tumor, will be featured in a poster on November 6 and an oral presentation on November 7. The data includes safety and efficacy updates. Immunocore is a biotech company developing immunomodulating medicines for cancer, infectious diseases, and auto...
10-29 13:00
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces the first patient dosing in a Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate, for HLA-A*02:01-positive patients with type 1 diabetes. IMC-S118AI is a bispecific molecule designed to protect beta cells under T cell attack by targeting preproinsulin peptide on beta cells and inhibiting autoreactive T cells. Preclinical data published in Science Advances showed its ability to selectively bind beta ce...
10-15 11:00
Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy
Immunic appoints Michael Panzara as CMO, granting inducement equity award as he takes charge of clinical and regulatory strategy.
04-28 18:38
Reported Sunday, KIMMTRAK Five-Year Phase 3 Data Shows Doubled Survival Likelihood Versus Investigator's Choice With Median OS Of 21.6 Months Versus 16.9 Months In Metastatic Uveal Melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaOS benefit observed across key subgroups, including patients with high tumor burden,
04-20 16:28
Immunocore Holdings To Present 5-Yr OS From KIMMTRAK Phase 3 Trial In Previously Untreated HLA-A*02:01 Positive Patients With Unresected Or mUM, At 2026 AACR Annual Meeting
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting(OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore
03-18 04:33
Invesco Provides Estimated Capital Gain Distribution Information for 2025
ATLANTA, Nov. 20, 2025 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ), a leading global provider of exchange-traded funds (ETFs), announced today that it expects to deliver capital gains distribut...
2025-11-20 21:30
